Topical and systemic medical treatments of basal cell carcinoma

P. Sollena, L. Del Regno, M. C. Fargnoli, Ketty Peris

Risultato della ricerca: Contributo in rivistaArticolo in rivista

4 Citazioni (Scopus)


Basal cell carcinoma (BCC) is the most common non melanoma skin cancer (NMSC) in white individuals over the age of 40 years. BCCs usually grow slowly and rarely metastasize, but can be locally invasive if neglected or of an aggressive subtype. The local tissue destruction caused by an untreated BCC can be extensive, therefore optimal treatment should lead to tumour clearance. Surgery and topical medical treatments are successful therapeutic options for most superficial and nodular BCC. Systemic medical treatments may be considered when surgical procedures are not recommended on the basis of the anatomical site and tumor extension, and patients' associated comorbidities. Expected cure rates and cosmetic outcome should be also carefully considered. A better understanding of the molecular mechanisms of BCC pathogenesis can lead to new developing target medical therapies, and data on their efficacy seem encouraging.
Lingua originaleEnglish
pagine (da-a)429-434
Numero di pagine6
RivistaGiornale Italiano di Dermatologia e Venereologia
Stato di pubblicazionePubblicato - 2015


  • basal cell carcinoma


Entra nei temi di ricerca di 'Topical and systemic medical treatments of basal cell carcinoma'. Insieme formano una fingerprint unica.

Cita questo